Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CSL760 in healthy adults
NCT04638634Phase 1Terminated
- Sponsor
- CSL Limited
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- IgG Antibodies, Recombinant Proteins and Enzymes, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, open-label trial of csl760 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CSL Limited. Primary endpoints: Total immunoglobulin (IgG) concentration of CSL760 at 91 days, Maximum concentration (Cmax) of CSL760 up to 91 days and 2 more. Started Feb 2021; status: terminated.
02
Drugs
csl760
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04638634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638634.